Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 10fludarabine 6Tacrolimus 5Mycophenolic Acid 5Melphalan 4ruxolitinib 3Whole-Body Irradiation 3Thiotepa 3Busulfan 3thymoglobulin 2fludarabine phosphate 2Stem Cell Transplantation 2Specimen Handling 2Clofarabine 2Biopsy 2vedolizumab 1belumosudil 1Tomography, Optical Coherence 1Sirolimus 1Radiotherapy 1Radiation 1Prednisone 1Methotrexate 1Mesna 1Low-Level Light Therapy 1LDP-02 1Immunoglobulin G 1Hematopoietic Stem Cell Transplantation 1Fecal Microbiota Transplantation 1Emapalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Graft vs Host Disease × belumosudil × Clear all
NCT07006506 2026-04-13

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
46 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡